USA - NASDAQ:SERA - US81749D1072 - Common Stock
The current stock price of SERA is 3.65 USD. In the past month the price increased by 18.12%. In the past year, price decreased by -47.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
SERA PROGNOSTICS INC-A
2749 E. Parleys Way, Suite 200
Salt Lake City UTAH US
CEO: Gregory C. Critchfield
Employees: 64
Phone: 18015050278
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
The current stock price of SERA is 3.65 USD. The price increased by 8.96% in the last trading session.
SERA does not pay a dividend.
SERA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SERA PROGNOSTICS INC-A (SERA) operates in the Health Care sector and the Biotechnology industry.
SERA PROGNOSTICS INC-A (SERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
SERA PROGNOSTICS INC-A (SERA) has a market capitalization of 138.92M USD. This makes SERA a Micro Cap stock.
ChartMill assigns a technical rating of 6 / 10 to SERA. When comparing the yearly performance of all stocks, SERA is a bad performer in the overall market: 86.45% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to SERA. The financial health of SERA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 13.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.27% | ||
| ROE | -37.1% | ||
| Debt/Equity | 0 |
For the next year, analysts expect an EPS growth of 21.7% and a revenue growth 118.18% for SERA